Results from a single-arm, multicentre, phase 2 trial suggest that patients with advanced cholangiocarcinoma with genetic alterations in fibroblast growth factor receptor (FGFR) might respond to treatment with BGJ398, a first-in-class selective pan-FGFR kinase inhibitor.

中文翻译：

---

BGJ398用于FGFR改变的晚期胆管癌。

单臂，多中心，2期试验的结果表明，患有晚期胆管癌且成纤维细胞生长因子受体（FGFR）发生遗传改变的患者可能对BGJ398的治疗有反应，BGJ398是首创的选择性pan-FGFR激酶抑制剂。